Xgeva治疗效果如何呢？

How effective is the treatment? A phase III clinical trial included people over 18 years of age who had started taking prednisone at a daily dose of ≥7.5 mg or an equivalent dose of steroids for more than 3 months, or who had been taking glucocorticoids for ≥3 months. Study subjects aged <50 years must have a history of osteoporotic fractures. People aged ≥50 years who continue to use glucocorticoids need a T-score less than or equal to -2.0 (or less than or equal to -1.0 with a history of fracture). Study subjects were randomized in a 1:1 ratio to receive Xgeva 60 mg subcutaneously every six months, or risedronate sodium 5 mg orally once a day for 24 months, while both received daily calcium and vitamin D supplements. 

Results: Among 795 study subjects, 590 completed the study. Xgeva was better than risedronate in estimating BMD of the lumbar spine and hip, both in people who started taking glucocorticoids and in people who continued to take glucocorticoids. In terms of adverse events, there were no significant differences in the occurrence of serious adverse events and fractures between the two treatment groups. Conclusion: After 24 months of treatment, Xgeva is better than risedronate in improving lumbar spine and hip BMD. The two drugs are similar in terms of safety. Denosumab may be a new option for the treatment of glucocorticoid-induced osteoporosis.

Developed by biotechnology company Amgen, it is a human monoclonal antibody and the first RANKL inhibitor to receive FDA approval. It works by preventing the development of osteoclasts, cells that break down bone (bone resorption). Xgeva is used to treat osteoporosis, treatment-induced bone loss, metastasis to the bone, and giant cell tumor of bone, and to reduce the risk of fractures in cancer patients. Xgeva is contraindicated in people with low blood calcium levels. The most common side effects of Xgeva are joint and muscle pain in the arms or legs.